Detalhe da pesquisa
1.
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Cancer
; 130(8): 1270-1280, 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153814
2.
A randomized, double-blind study of zinpentraxin alfa in patients with myelofibrosis who were previously treated with or ineligible for ruxolitinib: Stage 2 of a phase II trial.
Haematologica
; 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38268448
3.
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome.
Cancer
; 129(11): 1704-1713, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36932983
4.
Fms -like tyrosine kinase 3 positive acute myeloid leukemia.
Curr Opin Oncol
; 35(6): 589-593, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820093
5.
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Br J Haematol
; 199(3): 339-343, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002151
6.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33222197
7.
The changing landscape for patients with relapsed/refractory acute myeloid leukaemia.
Curr Opin Oncol
; 33(6): 635-641, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34474436
8.
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
Cancer
; 126(6): 1243-1252, 2020 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31860137
9.
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
Hematol Oncol
; 38(3): 372-380, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271957
10.
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib.
Hematol Oncol
; 37(4): 418-423, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30985017
11.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30515542
12.
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Ann Hematol
; 98(10): 2329-2338, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31392461
13.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol
; 183(1): 35-46, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30010187
14.
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study.
Hematol Oncol
; 36(1): 285-290, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-28512865
15.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29624703
16.
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice.
Ann Hematol
; 97(9): 1577-1580, 2018 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675611
17.
SARS-CoV-2 impact in a community-based hematological ward in an Italian Red Zone.
Ann Hematol
; 99(7): 1677-1678, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32535706
18.
Benda-EAM prior to ASCT and renal toxicity: Much ado about nothing.
Am J Hematol
; 94(4): E104-E105, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30663798
19.
BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.
Blood
; 118(12): 3419-25, 2011 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21816830
20.
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Blood
; 118(12): 3273-9, 2011 Sep 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791425